313 related articles for article (PubMed ID: 24857119)
1. Novel treatments for chronic lymphocytic leukemia and moving forward.
Brown JR; Porter DL; O'Brien SM
Am Soc Clin Oncol Educ Book; 2014; ():e317-25. PubMed ID: 24857119
[TBL] [Abstract][Full Text] [Related]
2. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
3. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapy in chronic lymphocytic leukemia: past, present, and future.
Danilov AV
Clin Ther; 2013 Sep; 35(9):1258-70. PubMed ID: 24054703
[TBL] [Abstract][Full Text] [Related]
6. Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?
Brown JR; Hallek MJ; Pagel JM
Am Soc Clin Oncol Educ Book; 2016; 35():e387-98. PubMed ID: 27249745
[TBL] [Abstract][Full Text] [Related]
7. Targeted Therapies Improve Outlook for Chronic Lymphocytic Leukemia.
Brower V
J Natl Cancer Inst; 2015 Dec; 107(12):djv396. PubMed ID: 26657100
[No Abstract] [Full Text] [Related]
8. Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
Suzumiya J; Takizawa J
Int J Hematol; 2020 May; 111(5):642-656. PubMed ID: 32253666
[TBL] [Abstract][Full Text] [Related]
9. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Thompson PA; Burger JA
Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
[TBL] [Abstract][Full Text] [Related]
10. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
Geethakumari PR; Awan F
Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
[TBL] [Abstract][Full Text] [Related]
12. [Chronic lymphatic leukemia].
Bergmann M; Wendtner CM
Dtsch Med Wochenschr; 2015 Apr; 140(7):479-82. PubMed ID: 25826029
[TBL] [Abstract][Full Text] [Related]
13. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
14. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
Byrd JC; Jones JJ; Woyach JA; Johnson AJ; Flynn JM
J Clin Oncol; 2014 Sep; 32(27):3039-47. PubMed ID: 25049322
[TBL] [Abstract][Full Text] [Related]
15. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.
Landau DA; Sun C; Rosebrock D; Herman SEM; Fein J; Sivina M; Underbayev C; Liu D; Hoellenriegel J; Ravichandran S; Farooqui MZH; Zhang W; Cibulskis C; Zviran A; Neuberg DS; Livitz D; Bozic I; Leshchiner I; Getz G; Burger JA; Wiestner A; Wu CJ
Nat Commun; 2017 Dec; 8(1):2185. PubMed ID: 29259203
[TBL] [Abstract][Full Text] [Related]
16. miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
Guinn D; Ruppert AS; Maddocks K; Jaglowski S; Gordon A; Lin TS; Larson R; Marcucci G; Hertlein E; Woyach J; Johnson AJ; Byrd JC
Leukemia; 2015 May; 29(5):1210-3. PubMed ID: 25486872
[No Abstract] [Full Text] [Related]
17. Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm.
Scheffold A; Stilgenbauer S
Curr Oncol Rep; 2020 Feb; 22(2):16. PubMed ID: 32025827
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.
Abou Zahr A; Bose P; Keating MJ
Expert Opin Pharmacother; 2017 Jun; 18(9):857-873. PubMed ID: 28446054
[TBL] [Abstract][Full Text] [Related]
19. Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
Desai AV; El-Bakkar H; Abdul-Hay M
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):314-22. PubMed ID: 25445466
[TBL] [Abstract][Full Text] [Related]
20. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target.
Morabito F; Gentile M; Seymour JF; Polliack A
Leuk Lymphoma; 2015; 56(12):3250-6. PubMed ID: 26062943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]